US · SUPN
Supernus Pharmaceuticals, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Rockville, MD 20850
- Website
- supernus.com
Price · as of 2024-12-31
$47.85
Market cap 3.14B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $110.03 | +129.95% |
| Intrinsic Value(DCF) | $32.21 | -32.69% |
| Graham-Dodd Method(GD) | $23.38 | -51.15% |
| Graham Formula(GF) | $22.44 | -53.1% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $242.43 | |||
| 2011 | $20.89 | $2,575.31 | |||
| 2012 | $7.85 | $28.34 | $990.96 | $0.00 | $0.00 |
| 2013 | $9.18 | $87.61 | $423,716.76 | $0.00 | $0.00 |
| 2014 | $11.77 | $248.66 | $1,730,239.42 | $4.04 | $415.53 |
| 2015 | $15.65 | $59.60 | $15,334.07 | $3.98 | $7.59 |
| 2016 | $26.35 | $52.94 | $1,813.21 | $13.10 | $101.06 |
| 2017 | $44.85 | $69.47 | $245.52 | $10.91 | $53.01 |
| 2018 | $37.61 | $69.60 | $291.16 | $19.39 | $89.24 |
| 2019 | $17.39 | $54.99 | $33.03 | $22.15 | $9.29 |
| 2020 | $26.71 | $65.40 | $41.71 | $24.74 | $94.39 |
| 2021 | $30.97 | $56.90 | $6.24 | $18.18 | $19.15 |
| 2022 | $34.97 | $84.45 | $14.01 | $19.99 | $25.43 |
| 2023 | $31.07 | $51.63 | $4.74 | $14.87 | $0.00 |
| 2024 | $32.07 | $110.03 | $8.32 | $23.38 | $22.44 |
AI valuation
Our deep-learning model estimates Supernus Pharmaceuticals, Inc.'s (SUPN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $110.03
- Current price
- $47.85
- AI upside
- +129.95%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$32.21
-32.69% upside
Graham-Dodd
$23.38
-51.15% upside
Graham Formula
$22.44
-53.1% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SUPN | Supernus Pharmaceuticals,… | $47.85 | 3.14B | +130% | -33% | -51% | -53% | 23.92 | 1.71 | 2.67 | 7.56 | 0.44 | 4.45 | 88.23% | 12.34% | 11.16% | 7.55% | 9.31% | 5.58% | 0.03 | — | 2.35 | 2.04 | -0.20 | 546962.00% | 894.00% | 5491.00% | 9.69% | 0.59 | 25.85% | 0.00% | 0.00% | 0.09% | 16.50 | 7.87 | 2.04 | 4.79 |
| AMRX | Amneal Pharmaceuticals, I… | $13.81 | 4.34B | +181% | -25% | -85% | -74% | 59.88 | 4.86 | 1.43 | -793.31 | — | -15.90 | 36.88% | 14.02% | 2.39% | 18.52% | 25.08% | 2.01% | 0.14 | 1.75 | 2.17 | 1.34 | 30.17 | -15789.00% | 805.00% | 2263.00% | 6.26% | 0.39 | 17.41% | 0.00% | 0.00% | 61.20% | 9.83 | 15.40 | 1.38 | 2.26 |
| BHC | Bausch Health Companies I… | $5.93 | 2.2B | +958% | +67% | — | +6% | 18.37 | -3.99 | 0.21 | 7.14 | — | -0.13 | 68.33% | 20.07% | 1.51% | -13.10% | 4.28% | 0.45% | -38.35 | 1.37 | 1.47 | 0.88 | 6.42 | -41538.00% | 711.00% | -2040.00% | 45.49% | 0.34 | 5.18% | 0.00% | 0.00% | 34.48% | 10.68 | 22.02 | 2.14 | 0.28 |
| CGON | CG Oncology, Inc. Common … | $58.80 | 4.74B | +6% | +153% | — | — | -27.73 | 5.93 | 1105.21 | -23.38 | -58.37 | 6.02 | -15.02% | -4722.13% | -3985.02% | -21.67% | -4199.76% | -20.82% | 0.01 | — | 24.63 | 24.09 | 0.16 | 4752.00% | 25470.00% | 6781.00% | -2.97% | -4.29 | -2916.46% | 0.00% | 0.00% | 0.00% | -19.55 | -28.15 | 923.25 | 68.35 |
| CNTA | Centessa Pharmaceuticals … | $26.86 | 3.61B | +34% | — | — | — | -7.88 | 4.63 | — | -6.73 | -25.25 | 4.63 | 0.00% | — | — | -73.93% | -398.61% | -50.32% | 0.29 | -19.93 | 9.25 | 9.09 | 1.20 | 3121.00% | -10000.00% | -1148.00% | -7.65% | -2.45 | -281.71% | 0.00% | 0.00% | 11.98% | -7.43 | -10.51 | — | 3.81 |
| GRAL | GRAIL, Inc. | $53.23 | 2.08B | -54% | -60% | -73% | — | — | 0.75 | 13.14 | -2.99 | — | 2.66 | -42.52% | -362.95% | -277.47% | 0.00% | -22.80% | 0.00% | 0.04 | — | 11.97 | 11.58 | 0.40 | -8251.00% | 1718.00% | -4866.00% | -15.46% | -3.75 | -16.71% | 0.00% | — | 0.29% | -2.11 | -3.77 | 7.66 | -1.71 |
| HCM | HUTCHMED (China) Limited | $14.33 | 2.59B | +159% | -38% | -61% | — | 74.95 | 3.72 | 4.49 | 147.56 | — | 3.74 | 44.64% | -6.94% | 5.99% | 5.06% | 131.28% | 2.95% | 0.12 | -15.22 | 2.83 | 2.67 | -4.55 | -6333.00% | -2480.00% | -10934.00% | -0.62% | 0.00 | 62.24% | 0.00% | 0.00% | 1.28% | -47.63 | -119.38 | 3.30 | 3.49 |
| INDV | Indivior Pharmaceuticals … | $32.72 | 4.08B | +249% | +42% | -77% | -38% | 19.04 | -40.38 | 3.23 | 12.71 | 0.18 | -39.58 | 80.23% | 21.15% | 16.95% | -93.96% | -87.53% | 16.67% | -0.62 | 5.82 | 0.71 | 0.49 | -0.44 | 1083333.00% | 429.00% | -142857.00% | -2.33% | -0.03 | 35.36% | 0.00% | 0.00% | 5.03% | 14.75 | -41.54 | 3.12 | 3.05 |
| LNTH | Lantheus Holdings, Inc. | $74.91 | 5.09B | +40% | +25% | -60% | -60% | 22.05 | 4.73 | 3.34 | 14.36 | — | 40.39 | 61.10% | 20.16% | 15.15% | 21.45% | 30.32% | 11.10% | 0.00 | 15.74 | 2.70 | 2.15 | -1.07 | -2179.00% | 50.00% | -2820.00% | 6.88% | 1.17 | 46.40% | 0.00% | 0.00% | 1.26% | 15.41 | 13.53 | 3.11 | 4.60 |
| PRGO | Perrigo Company plc | $13.22 | 1.82B | -63% | -63% | — | — | -1.20 | 0.58 | 0.40 | -1.52 | -0.17 | 1.94 | 35.14% | 8.07% | -33.51% | -39.29% | 6.99% | -15.68% | 0.01 | 2.11 | 2.76 | 1.13 | 0.62 | 72320.00% | -275.00% | -4068.00% | 8.49% | 0.24 | 2.96% | 9.32% | -11.20% | 217.29% | 3.54 | 8.37 | 0.29 | 0.46 |
| XENE | Xenon Pharmaceuticals Inc… | $43.23 | 3.34B | — | -58% | — | — | -9.75 | 5.80 | 449.63 | -8.27 | -21.74 | 5.80 | 66.09% | -4974.27% | -4612.13% | -51.76% | -419.58% | -48.34% | 0.01 | — | 13.13 | 13.17 | 0.56 | 4485.00% | — | 5175.00% | -8.30% | -6.68 | -314.81% | 0.00% | 0.00% | 1.71% | -7.59 | -10.11 | 377.51 | 35.64 |
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
- CEO
- Jack A. Khattar
- Employees
- 674
- Beta
- 0.72
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($32.21 ÷ $47.85) − 1 = -32.69% (DCF, example).